<DOC>
	<DOC>NCT01438229</DOC>
	<brief_summary>This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.</brief_summary>
	<brief_title>Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients</brief_title>
	<detailed_description>Demonstrate the safety and efficacy of the St. Jude Medical Radiofrequency (RF) Renal Denervation System in the treatment of patients with resistant hypertension. Safety Marker - All adverse events Efficacy Marker - Office blood pressure</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior to enrollment Age ≥18 and ≤80 years old Able and willing to provide written informed consent to participate in the study Able and willing to comply with the required followup schedule Prior renal artery intervention (balloon angioplasty or stenting) Evidence of renal artery atherosclerosis (defined as a stenotic severity of &gt;30%) in either renal artery Multiple main renal arteries in either kidney Main renal arteries &lt;4 mm in diameter or &lt;20 mm in length eGFR of &lt;45 mL/min per 1.73 m2 using the MDRD formula Type 1 diabetes Renovascular hypertension or hypertension secondary to other renal disorders (glomerulonephritis, polycystic kidney disease, endstage renal failure) Others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Catheter-based renal artery ablation</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Resistant to Conventional Therapy</keyword>
</DOC>